Alydar Pharmaceuticals Inc., of Mountain View, Calif., added Wittko Francke, Kenji Mori, Stefan Schulz and Rony Seger to its scientific advisory board.

Athersys Inc., of Cleveland, added William Lehmann as vice president of corporate development and Youssef Bennani as director of medicinal chemistry.

Aviron Inc., of Mountain View, Calif., named Mike Makris vice president, controller.

Biogen Inc., of Cambridge, Mass., named Robert Hamm senior vice president-international, added Guy-Charles Fanneau dela Horie as vice president, strategic commercial operations-international and appointed Patrick Vink vice president, sales, responsible for international affiliates.

Connetics Corp., of Palo Alto, Calif., appointed Ross Macdonald vice president, business development.

CytoGenix Inc., of Houston, appointed Yin Chen vice president of research and development and added Charles Boyd and Nhan Nguyen to its board.

Ecopia BioSciences Inc., of Montreal, appointed Peter McBride vice president, investor relations and communications.

Epimmune Inc., of San Diego, named Michael McClurg vice president, business development.

GeneFormatics Inc., of San Diego, added Edward Lanphier to its board.

Genentech Inc., of South San Francisco, added Ronald Branning as vice president, global quality, and promoted Paula Jardieu to senior vice president, development sciences; Frank Jackson to vice president, Vacaville product operations; and Bernice Wells to vice president, product development.

GenStar Therapeutics Corp., of San Diego, appointed Wei-Wei Zhang chairman of its scientific advisory board, added Yawen Chiang as senior vice president of research and development and promoted Xiangming Fang to vice president of vector development and hemophilia.

Large Scale Biology Corp., of Vacaville, Calif., named John Fowler president and a director and Ronald Artale chief financial officer.

Locus Discovery Inc., of Blue Bell, Pa., appointed Robert Gussin to its board.

Medarex Inc., of Princeton, N.J., appointed Thomas Davis director of clinical science, Michael Yellin director of rheumatology and immunology and Richard Romasz director of clinical operations.

Neurome Inc., of La Jolla, Calif., appointed Tomas Hokfelt to its scientific advisory board.

Oxigene Inc., of Watertown, Mass., added Robert Kerbel to its scientific advisory board.

Paradigm Genetics Inc., of Research Triangle Park, N.C., formed a metabolomics scientific advisory board compromised of Ralph Bradshaw, John Hartigan, Ian Jardine, Roger McClellan, Ian Scott and Evgeni Selkov.

Protarga Inc., of King of Prussia, Pa., appointed Lee Schacter senior vice president, clinical development, and Charmaine Fedick vice president, clinical operations.